{"filing":{"accession_number":"0001493152-26-029516","cik":"0001857030","ticker":"INCR","company_name":"Intercure Ltd.","form":"6-K","filing_date":"2026-06-22","report_date":null,"primary_document":"form6-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1857030/000149315226029516/form6-k.htm"},"events":[{"id":12651,"run_id":11223,"accession_number":"0001493152-26-029516","anchor_item_number":"EX-99.1","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"InterCure announced a binding term sheet for a private placement of NIS 22 million (potentially NIS 54 million) involving issuance of 7,895,143 ordinary shares at NIS 2.75 per share plus warrants to purchase an additional 7,895,143 shares. This is an unregistered equity issuance raising capital, with the securities explicitly noted as not registered under the Securities Act of 1933. The participation of the CEO and leading pharma-focused hedge funds, combined with the material capital raise and dilutive warrant component, makes this a significant dilutive issuance material to investors.","company_name":"Intercure Ltd.","ticker":"INCR","filing_date":"2026-06-22","form":"6-K","submitted_at":null,"items":[{"id":9559,"accession_number":"0001493152-26-029516","item_number":"EX-99.1","item_title":"ex99-1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"InterCure announced a binding term sheet for a private placement of NIS 22 million (potentially NIS 54 million) involving issuance of 7,895,143 ordinary shares at NIS 2.75 per share plus warrants to purchase an additional 7,895,143 shares. This is an unregistered equity issuance raising capital, with the securities explicitly noted as not registered under the Securities Act of 1933. The participation of the CEO and leading pharma-focused hedge funds, combined with the material capital raise and dilutive warrant component, makes this a significant dilutive issuance material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T15:30:00.485378+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9559,"accession_number":"0001493152-26-029516","item_number":"EX-99.1","item_title":"ex99-1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"InterCure announced a binding term sheet for a private placement of NIS 22 million (potentially NIS 54 million) involving issuance of 7,895,143 ordinary shares at NIS 2.75 per share plus warrants to purchase an additional 7,895,143 shares. This is an unregistered equity issuance raising capital, with the securities explicitly noted as not registered under the Securities Act of 1933. The participation of the CEO and leading pharma-focused hedge funds, combined with the material capital raise and dilutive warrant component, makes this a significant dilutive issuance material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T15:30:00.485378+00:00","company_name":"Intercure Ltd.","ticker":"INCR","filing_date":"2026-06-22"}]}